View in EDS

Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.

Saved in:
Bibliographic Details
Title: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
Authors: Sharma MR; START Center for Cancer Research-Midwest, Grand Rapids, MI., Powderly J; Carolina BioOncology Institute, Huntersville, NC., Kuboki Y; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan., Strickler JH; Duke University Medical Center, Durham, NC., Perets R; Rambam Medical Center and Technion-Israel Institute of Technology, Haifa, Israel., Cohen JE; Hadassah Hebrew University Medical Center, Jerusalem, Israel., Raimbourg J; Institut de Cancérologie de l'Ouest, Saint Herblain, France., Nakajima TE; Kyoto University Graduate School of Medicine, Kyoto-Shi, Japan., Yamamoto N; National Cancer Center Hospital, Tokyo, Japan., Cruz-Correa M; The University of Puerto Rico, Medical Sciences Campus, and Pan-American Center for Oncology Trials, San Juan, Puerto Rico., O'Neil B; Oncology, Community Health Network North Cancer Center, Indianapolis, IN., Ghiringhelli F; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France., Raghav K; The University of Texas MD Anderson Cancer Center, Houston, TX., Cecchini M; Yale University School of Medicine, New Haven, CT., Bar J; Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.; The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel., Hunter Z; AbbVie Inc, North Chicago, IL., Burns M; AbbVie Inc, North Chicago, IL., Blaney M; AbbVie Inc, North Chicago, IL., Morrison-Thiele G; AbbVie Inc, North Chicago, IL., Aristide MN; AbbVie Inc, North Chicago, IL., Freise KJ; AbbVie Inc, North Chicago, IL., Li R; AbbVie Inc, North Chicago, IL., Li M; AbbVie Inc, North Chicago, IL., Vasilopoulos A; AbbVie Inc, North Chicago, IL., Biesdorf C; AbbVie Inc, North Chicago, IL., Sommerhalder D; NEXT Oncology, San Antonio, TX.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2026 Jul 10; Vol. 44 (20), pp. 1876-1888. Date of Electronic Publication: 2026 May 01.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42066233
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sharma+MR%22">Sharma MR</searchLink>; START Center for Cancer Research-Midwest, Grand Rapids, MI.<br /><searchLink fieldCode="AU" term="%22Powderly+J%22">Powderly J</searchLink>; Carolina BioOncology Institute, Huntersville, NC.<br /><searchLink fieldCode="AU" term="%22Kuboki+Y%22">Kuboki Y</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Strickler+JH%22">Strickler JH</searchLink>; Duke University Medical Center, Durham, NC.<br /><searchLink fieldCode="AU" term="%22Perets+R%22">Perets R</searchLink>; Rambam Medical Center and Technion-Israel Institute of Technology, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Cohen+JE%22">Cohen JE</searchLink>; Hadassah Hebrew University Medical Center, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Raimbourg+J%22">Raimbourg J</searchLink>; Institut de Cancérologie de l'Ouest, Saint Herblain, France.<br /><searchLink fieldCode="AU" term="%22Nakajima+TE%22">Nakajima TE</searchLink>; Kyoto University Graduate School of Medicine, Kyoto-Shi, Japan.<br /><searchLink fieldCode="AU" term="%22Yamamoto+N%22">Yamamoto N</searchLink>; National Cancer Center Hospital, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Cruz-Correa+M%22">Cruz-Correa M</searchLink>; The University of Puerto Rico, Medical Sciences Campus, and Pan-American Center for Oncology Trials, San Juan, Puerto Rico.<br /><searchLink fieldCode="AU" term="%22O'Neil+B%22">O'Neil B</searchLink>; Oncology, Community Health Network North Cancer Center, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Ghiringhelli+F%22">Ghiringhelli F</searchLink>; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.<br /><searchLink fieldCode="AU" term="%22Raghav+K%22">Raghav K</searchLink>; The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Cecchini+M%22">Cecchini M</searchLink>; Yale University School of Medicine, New Haven, CT.<br /><searchLink fieldCode="AU" term="%22Bar+J%22">Bar J</searchLink>; Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.; The Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Hunter+Z%22">Hunter Z</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Burns+M%22">Burns M</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Blaney+M%22">Blaney M</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Morrison-Thiele+G%22">Morrison-Thiele G</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Aristide+MN%22">Aristide MN</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Freise+KJ%22">Freise KJ</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Li+R%22">Li R</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Vasilopoulos+A%22">Vasilopoulos A</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Biesdorf+C%22">Biesdorf C</searchLink>; AbbVie Inc, North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Sommerhalder+D%22">Sommerhalder D</searchLink>; NEXT Oncology, San Antonio, TX.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2026 Jul 10; Vol. 44 (20), pp. 1876-1888. <i>Date of Electronic Publication: </i>2026 May 01.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42066233
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO-25-01525
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1876
    Titles:
      – TitleFull: Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sharma MR
      – PersonEntity:
          Name:
            NameFull: Powderly J
      – PersonEntity:
          Name:
            NameFull: Kuboki Y
      – PersonEntity:
          Name:
            NameFull: Strickler JH
      – PersonEntity:
          Name:
            NameFull: Perets R
      – PersonEntity:
          Name:
            NameFull: Cohen JE
      – PersonEntity:
          Name:
            NameFull: Raimbourg J
      – PersonEntity:
          Name:
            NameFull: Nakajima TE
      – PersonEntity:
          Name:
            NameFull: Yamamoto N
      – PersonEntity:
          Name:
            NameFull: Cruz-Correa M
      – PersonEntity:
          Name:
            NameFull: O'Neil B
      – PersonEntity:
          Name:
            NameFull: Ghiringhelli F
      – PersonEntity:
          Name:
            NameFull: Raghav K
      – PersonEntity:
          Name:
            NameFull: Cecchini M
      – PersonEntity:
          Name:
            NameFull: Bar J
      – PersonEntity:
          Name:
            NameFull: Hunter Z
      – PersonEntity:
          Name:
            NameFull: Burns M
      – PersonEntity:
          Name:
            NameFull: Blaney M
      – PersonEntity:
          Name:
            NameFull: Morrison-Thiele G
      – PersonEntity:
          Name:
            NameFull: Aristide MN
      – PersonEntity:
          Name:
            NameFull: Freise KJ
      – PersonEntity:
          Name:
            NameFull: Li R
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: Vasilopoulos A
      – PersonEntity:
          Name:
            NameFull: Biesdorf C
      – PersonEntity:
          Name:
            NameFull: Sommerhalder D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 07
              Text: 2026 Jul 10
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 44
            – Type: issue
              Value: 20
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1